OncoCyte Corporation
Index- P/E- EPS (ttm)-0.66 Insider Own1.80% Shs Outstand118.61M Perf Week20.74%
Market Cap29.62M Forward P/E- EPS next Y-0.33 Insider Trans22.52% Shs Float106.54M Perf Month-19.52%
Income-64.10M PEG- EPS next Q-0.09 Inst Own59.70% Short Float / Ratio1.17% / 2.85 Perf Quarter-6.67%
Sales8.10M P/S3.66 EPS this Y-57.70% Inst Trans-3.83% Short Interest1.24M Perf Half Y-62.67%
Book/sh0.65 P/B0.43 EPS next Y11.10% ROA-40.40% Target Price- Perf Year-81.46%
Cash/sh0.31 P/C0.91 EPS next 5Y- ROE-90.80% 52W Range0.20 - 1.68 Perf YTD-12.75%
Dividend- P/FCF- EPS past 5Y-11.40% ROI-95.70% 52W High-83.33% Beta1.66
Dividend %- Quick Ratio2.80 Sales past 5Y- Gross Margin-8.10% 52W Low40.00% ATR0.05
Employees110 Current Ratio2.80 Sales Q/Q0.00% Oper. Margin- RSI (14)45.50 Volatility10.84% 18.52%
OptionableYes Debt/Eq0.00 EPS Q/Q46.60% Profit Margin- Rel Volume0.86 Prev Close0.31
ShortableYes LT Debt/Eq0.00 EarningsMar 29 AMC Payout- Avg Volume436.49K Price0.28
Recom2.60 SMA20-6.09% SMA50-23.52% SMA200-55.27% Volume375,243 Change-8.50%
May-24-22Downgrade Stephens Overweight → Equal-Weight
Mar-14-22Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Jan-07-22Initiated Stephens Overweight $3.10
Jan-06-22Resumed Piper Sandler Overweight $3.10
Mar-17-21Resumed Needham Buy $8
Jan-07-21Upgrade The Benchmark Company Speculative Buy → Buy $6
Dec-16-20Upgrade Piper Sandler Neutral → Overweight $2 → $4
Nov-30-20Initiated BTIG Research Buy $5
Nov-10-20Initiated KeyBanc Capital Markets Overweight $5
Jul-30-20Reiterated The Benchmark Company Speculative Buy $7 → $6
Show Previous Ratings
Mar-29-23 04:01PM
Mar-15-23 04:01PM
Mar-02-23 09:00AM
Feb-22-23 08:00AM
Dec-16-22 08:19AM
08:00AM Loading…
Nov-30-22 06:05PM
Nov-10-22 04:30PM
Oct-27-22 04:01PM
Oct-06-22 08:00AM
Sep-07-22 08:00AM
Aug-31-22 04:01PM
Aug-30-22 04:27PM
Aug-24-22 08:00AM
04:05PM Loading…
Aug-10-22 04:05PM
Aug-03-22 04:01PM
Aug-01-22 11:33AM
Jul-27-22 04:01PM
Jul-13-22 08:00AM
Jul-06-22 08:00AM
Jun-22-22 08:00AM
Jun-15-22 07:15AM
May-26-22 05:00PM
May-11-22 04:05PM
May-05-22 08:00AM
Apr-28-22 04:01PM
Apr-27-22 04:30PM
Apr-22-22 09:26AM
10:01PM Loading…
Apr-13-22 10:01PM
Apr-11-22 08:00AM
Mar-28-22 08:00AM
Mar-10-22 04:05PM
Mar-01-22 04:05PM
Feb-21-22 07:26AM
Feb-10-22 08:00AM
Jan-18-22 04:05PM
Jan-06-22 09:43AM
Jan-04-22 08:00AM
Dec-09-21 06:00PM
Dec-08-21 08:00AM
Dec-06-21 08:00AM
Dec-02-21 08:00AM
Nov-22-21 06:14AM
Nov-09-21 04:05PM
Nov-04-21 08:00AM
Nov-02-21 03:02PM
Oct-27-21 08:00AM
Oct-26-21 04:05PM
Oct-08-21 09:46AM
Oct-07-21 08:00AM
Sep-30-21 08:00AM
Sep-20-21 11:35AM
Sep-16-21 08:00AM
Sep-13-21 08:00AM
Sep-07-21 04:05PM
Aug-23-21 09:13AM
Aug-18-21 08:49AM
Aug-17-21 08:00AM
Aug-10-21 04:01PM
Aug-09-21 08:00AM
Aug-03-21 03:00PM
Jul-27-21 10:35AM
Jul-08-21 05:34AM
Jun-22-21 08:00AM
Jun-15-21 08:03AM
Jun-03-21 08:00AM
Jun-01-21 08:00AM
May-24-21 05:26AM
May-17-21 04:01PM
May-06-21 08:00AM
May-04-21 04:01PM
Apr-28-21 04:31PM
Apr-19-21 08:00AM
Apr-14-21 09:02AM
Apr-10-21 01:31PM
Apr-06-21 04:05PM
Mar-23-21 01:44AM
Mar-16-21 04:01PM
Mar-15-21 08:00AM
Mar-09-21 08:00AM
Mar-04-21 08:00AM
Mar-03-21 04:01PM
Feb-25-21 08:00AM
Feb-23-21 04:05PM
Feb-16-21 04:05PM
Feb-09-21 04:05PM
Feb-05-21 06:06PM
Feb-04-21 04:05PM
Feb-02-21 09:35AM
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Arno AndrewDirectorDec 23Buy0.35250,00087,875532,049Dec 28 04:05 PM
Gutfreund John PeterDirectorDec 23Buy0.3375,00024,72875,000Dec 28 04:05 PM
KINGSLEY ALFRED DDirectorDec 22Buy0.2825,0007,125439,111Dec 27 06:47 PM
ANDREWS RONALD ASBURYFormer CEODec 01Option Exercise0.00250,0000583,212Dec 09 08:23 PM
Last Andrew J.DirectorAug 17Buy0.8720,00017,40070,170Aug 19 08:00 AM
Arno AndrewDirectorAug 17Buy0.9015,00013,50015,000Aug 19 08:00 AM
Arno AndrewDirectorAug 16Buy0.97115,523112,057282,049Aug 17 08:15 PM
ANDREWS RONALD ASBURYPresident & CEOAug 16Buy0.9640,00038,400333,212Aug 18 04:05 PM
GRIFFITH MELINDADirectorAug 16Buy1.0010,00010,00030,000Aug 17 08:18 PM
Carter Jennifer L.DirectorAug 16Buy0.9510,5009,97530,500Aug 17 08:17 PM
Arno AndrewDirectorAug 15Buy0.9334,47732,064166,526Aug 17 08:15 PM
Gutfreund John PeterDirectorAug 15Buy0.9325,00023,25025,000Aug 17 08:19 PM
KINGSLEY ALFRED DDirectorAug 15Buy0.9710,0009,700414,111Aug 17 08:20 PM
Last Andrew J.DirectorJun 24Option Exercise0.0010,000040,170Jul 19 04:05 PM
Arno AndrewDirectorJun 24Option Exercise0.0010,0000122,049Jul 19 04:05 PM
KINGSLEY ALFRED DDirectorJun 24Option Exercise0.0010,0000394,111Jul 19 04:05 PM
Carter Jennifer L.DirectorJun 24Option Exercise0.0010,000010,000Jul 19 04:05 PM
GRIFFITH MELINDADirectorJun 24Option Exercise0.0010,000010,000Jul 19 04:05 PM
Redmond Cavan M.DirectorJun 24Option Exercise0.0010,0000120,863Jul 19 04:05 PM
PURA VIDA INVESTMENTS, LLC10% OwnerJun 24Sale1.0399,386102,6357,427,202Jun 28 07:48 PM
Yu LiVP Cntrllr/Prncpl Acctng OffcrMay 18Option Exercise0.0025,000025,000May 19 05:58 PM
Yu LiVP Cntrllr/Prncpl Acctng OffcrMay 18Sale1.148,1289,26616,872May 19 05:58 PM
BROADWOOD PARTNERS, L.P.10% OwnerApr 14Buy1.336,003,7528,000,00023,353,697Apr 15 06:13 PM
PURA VIDA INVESTMENTS, LLC10% OwnerApr 14Buy1.335,931,7077,887,8508,532,663Apr 18 09:55 PM